A recent publication reported the identification of another ten genes which may predispose to type 2 diabetes (T2DM), bringing the current total to around fifty. However, the impact of these genetic studies from a clinical perspective remains minimal. Forty years after the discovery of the first genes involved in diabetes susceptibility, should we be querying the value of expensive ‘factory floor’ genetics?